FAS
TEVA icon

Formuepleje A/S’s Teva Pharmaceuticals TEVA Stock Holding History

Formuepleje A/S’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,806,500
Closed -$31.8M – 66
2017
Q3 		$31.8M Buy
1,806,500
+59,000
+3% +$1.33M 3.49% 11
2017
Q2 		$58.1M Buy
1,747,500
+659,700
+61% +$20.4M 6.05% 4
2017
Q1 		$34.9M Buy
1,087,800
+125,100
+13% +$4.27M 4.17% 9
2016
Q4 		$34.9M Buy
962,700
+578,000
+150% +$23.1M 4.59% 6
2016
Q3 		$17.7M Buy
+384,700
New +$20.1M 2.39% 19
2014
Q2 		– Sell
-1,190,400
Closed -$62.9M – 53
2014
Q1 		$62.9M Buy
+1,190,400
New +$55M 7.39% 6

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Formuepleje A/S's TEVA Position: Q4 2017 in Review

Formuepleje A/S sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,806,500 shares — an estimated $31.8M sold.

Formuepleje A/S first reported a position in TEVA in Q1 2014 and held it in 6 quarters. The position peaked at $62.9M in Q1 2014. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Formuepleje A/S reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Formuepleje A/S sold 1,806,500 Teva Pharmaceuticals shares in Q4 2017, an estimated $31.8M.
  • Formuepleje A/S first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • Formuepleje A/S's Teva Pharmaceuticals position peaked at $62.9M in Q1 2014.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Formuepleje A/S's 13F filing for Q4 2017, filed 27 Aug 2026.